CTLA4 and neoplasm: Cancer immunotherapies that block inhibitory checkpoint receptors on T cells, such as cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed death receptor 1 (PD-1), have resulted in remarkable, long-term tumor control in a subset of patients (1–3).